Current therapies for Parkinson’s disease and related conditions primarily treat symptoms but don’t stop the underlying process causing the disease.

Increasing evidence suggests that toxic clumps of proteins called alpha-synuclein are among the primary drivers of damage to neurons. My team and I developed a synthetic molecule that can block these proteins from clumping and spreading in the brains of mice, ultimately reducing symptoms of disease.

This molecule, called SK-129, acts like a molecular brace: It binds to several parts of alpha-synuclein and holds the protein in a shape that makes it less likely to stick to other ones. It binds especially strongly to early forms of these toxic clumps, preventing them from growing and forming new ones.

Beyond SK-129, our research highlights the broader potential of the class of molecules to which it belongs:........

© The Conversation